FindTrial
Sign In

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03066661
Enrollment
Unknown
Registered
2017-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2019-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancers With NTRK, ROS1, or ALK Gene Fusions

Brief summary

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Interventions

DRUGEntrectinib

Open-label expanded access, capsules

Sponsors

Hoffmann-La Roche
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion * Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial * Willing and able to provide written, signed informed consent * Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion criteria

* Currently enrolled in an ongoing clinical study with any other investigational agent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026